3-甲氧基-4-甲氧羰基苯硼酸 | 603122-41-4

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲氧基-4-甲氧羰基苯硼酸
• 中文别名: 3-甲氧基-4-甲氧基羰基苯硼酸
• 英文名称: (3-methoxy-4-(methoxycarbonyl)phenyl)boronic acid
• 英文别名: 4-methoxycarbonyl-3-methoxyphenylboronic acid；3-Methoxy-4-methoxycarbonylphenylboronic acid；(3-methoxy-4-methoxycarbonylphenyl)boronic acid
• CAS: 603122-41-4
• 化学式: C₉H₁₁BO₅
• mdl: MFCD07366483
• 分子量: 209.994
• InChiKey: YCXPWNGIPLGCOJ-UHFFFAOYSA-N

物化性质

• 沸点：
  397.4±52.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.53
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2931900090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P301+P310
• 危险品运输编号：
  2811
• 危险性描述：
  H301

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Methoxy-4-methoxycarbonylphenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Methoxy-4-methoxycarbonylphenylboronic acid
CAS number: 603122-41-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H11BO5
Molecular weight: 210.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲氧基-4-甲氧羰基苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 lithium hydroxide monohydrate 、 水 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 2-methoxy-4-(1-methylimidazol-2-yl)benzoic acid
  参考文献：
  名称：

  [EN] ARYL AND HETEROARYL-CARBOXAMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS TYK2 INHIBITORS
  [FR] COMPOSÉS HÉTÉROARYLE SUBSTITUÉS PAR ARYLE ET HÉTÉROARYLE-CARBOXAMIDE UTILES EN TANT QU'INHIBITEURS DE TYK2

  摘要：

  公开了一种化合物，其为新颖的羧酰胺取代化合物，化学式为（I）；以及其制备方法，包含它们的药物组成物和它们作为酪氨酸激酶2（Tyk2）抑制剂在治疗中的用途。

  公开号：

  WO2021204626A1
• 作为产物：
  描述：

  3-甲氧基-4-甲氧羰基苯硼酸频那醇酯 在 sodium periodate 、 ammonium acetate 作用下， 以 水 、 丙酮 为溶剂， 生成 3-甲氧基-4-甲氧羰基苯硼酸
  参考文献：
  名称：

  发现一系列新型的联苯苯甲酸衍生物，作为具有良好口服生物利用度的有效和选择性人β3-肾上腺素能受体激动剂。第一部分

  摘要：

  一种新型的含有基于铅化合物8i的苯甲酸部分的联苯类似物已被鉴定为具有良好口服生物利用度和长血浆半衰期的有效和选择性的人β3肾上腺素能受体（β3-AR）激动剂。在研究了铅化合物8i的末端苯环上的进一步取代基作用后，我们发现R位置的更多亲脂取代提高了效能和选择性。这些研究的结果是，在效力，选择性和药代动力学方面取得了最佳平衡，确定了10a和10e是领先的候选药物。另外，评价化合物10a和10e对于由卡巴胆碱引起的膀胱内压力升高是有效的，例如在麻醉狗中膀胱过度活动模型。

  DOI：

  10.1021/jm701324c

文献信息

• Aminoalcohol derivatives
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20040006143A1

  公开（公告）日：2004-01-08

  The present invention relates to a compound formula [I]: 1 wherein 2 Y is bond, —O—(CH 2 ) n — (in which n is 1, 2, 3 or 4), etc., Z is cyano, tetrazolyl, etc., R 1 is hydrogen, lower alkyl, etc., R 2 is hydrogen or an amino protective group, R 3 is hydrogen or lower alkyl, R 4 is hydrogen or lower alkyl, R 5 and R 8 are each independently hydrogen, halogen, hydroxy, lower alkyl, etc., R 6 is hydrogen, lower alkyl, etc., R 9 is hydrogen or lower alkyl, and i is 1 or 2, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.

  本发明涉及一种化合物公式[I]: 1 其中 2 Y是键，—O—(CH 2 ) n — (其中n是1、2、3或4)，等等， Z是氰基，四唑基，等等， R 1 是氢，低级烷基，等等， R 2 是氢或氨基保护基团， R 3 是氢或低级烷基， R 4 是氢或低级烷基， R 5 和R 8 各自独立是氢，卤素，羟基，低级烷基，等等， R 6 是氢，低级烷基，等等， R 9 是氢或低级烷基，以及 i是1或2， 或其盐。本发明的化合物[I]及其药用可接受的盐对于预防性和/或治疗性治疗尿频或尿失禁是有用的。
• [EN] IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZO[2,1-B][1,3,4]THIADIAZOLE
  申请人：CT NAC DE INVESTIGACIONES ONCO

  公开号：WO2010112874A1

  公开（公告）日：2010-10-07

  There is provided compounds of formula (I): wherein R1, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K) is desired and/or required, and particularly in the treatment of cancer.

  提供了以下式(I)的化合物：其中R1、R2和R3的含义如描述中所示，以及其药学上可接受的酯、酰胺、溶剂合物或盐，这些化合物在治疗需要或期望抑制蛋白激酶或脂质激酶（例如PI3-K，特别是I类PI3K）的疾病中非常有用，特别是在癌症治疗中。
• An unusual 1,2-aryl shift in palladium-catalyzed cross-coupling ethoxycarbonylation of arylboronic acids with α-iminoesters
  作者：Cheng Qian、Jiayan Chen、Meiqin Fu、Shiya Zhu、Wen-Hua Chen、Huanfeng Jiang、Wei Zeng

  DOI：10.1039/c3ob41011k

  日期：——

  The Pd-catalyzed cross-coupling ethoxycarbonylation of aryl boronic acids with N-aryl-α-iminoesters affords aryl carboxylic esters via carbonyl-imino σ bond cleavage. This unprecedented mode of reaction allows regioselective installation of the ethoxycarbonyl group into target molecules. Mechanism studies have revealed that an unusual 1,2-aryl shift process is involved in the transformation.

  钯催化的芳基硼酸与N-芳基α-亚胺酯的交叉偶联乙氧羰基化反应，通过碳基-亚胺σ键断裂形成芳基羧酸酯。这种前所未有的反应模式允许将乙氧羰基团区域选择性地安装到目标分子中。机理研究表明，在该转化过程中涉及了一种不寻常的1,2-芳基迁移过程。
• Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7<i>H</i>-thieno[3,2-<i>b</i>]pyran-7-ones Designed as Next Generation PI3K Inhibitors
  作者：Guillermo A. Morales、Joseph R. Garlich、Jingdong Su、Xiaodong Peng、Jessica Newblom、Kevin Weber、Donald L. Durden

  DOI：10.1021/jm301522m

  日期：2013.3.14

  has made PI3K a consensus target to inhibit as illustrated by more than 15 inhibitors now in clinical trials. Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3K vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials. This inhibitor has properties that impart more in vivo activity than should be warranted

  磷脂酰肌醇-3-激酶（PI3K）通路在多种肿瘤中的失调使PI3K成为抑制的共识靶标，目前临床试验中已使用15种以上的抑制剂进行了说明。我们先前的工作是建立在早期的首创的多激酶抑制剂LY294002的基础上的，导致了唯一的PI3K血管靶向PI3K抑制剂前药SF1126，该药物现已完成I期临床试验。该抑制剂具有比其酶促效力应赋予的更多的体内活性，该酶促效力通常远低于其他临床阶段的PI3K抑制剂。我们着手探索保留了这些特性并同时展现出对PI3K更高效力的支架。这项工作导致发现了5-morpholino-7 H -thieno [3,2- b] pyran-7-one系统作为潜在的PI3K抑制剂新化合物类别的基础，对PI3K具有增强的效力。这些化合物的合成和基于癌症干细胞的活性在本文中报道。
• Mild Silver(I)-Mediated Regioselective Iodination and Bromination of Arylboronic Acids
  作者：Raed M. Al-Zoubi、Dennis G. Hall

  DOI：10.1021/ol100537x

  日期：2010.6.4

  A convenient and regioselective silver(I)-mediated electrophilic iodination and bromination reaction of arylboronic acids has been developed. The boronic acid does not require protection prior to the reaction, which can be performed on a multigram scale with moderate to excellent yields. A mild, simple, and effective method is disclosed to provide ortho-haloarylboronic acids that can be used as useful

  已经开发了方便且区域选择性的银（I）介导的芳基硼酸的亲电子碘化和溴化反应。硼酸在反应之前不需要保护，该保护可以在数克规模上以中等至极好的收率进行。公开了一种温和，简单且有效的方法，以提供邻-卤代芳基硼酸，其可用作选择性顺序Suzuki-Miyaura交叉偶联反应中的有用中间体，从而以高收率提供邻-三芳基衍生物。